



# Uplizna® - Inebilizumab Injection

Phone: (877) 246-9104

Fax: (800) 783-9146

www.biotechrx.com

PATIENT INFORMATION (Complete or fax existing chart)		PRESCRIBER INFORMATION	
Patient Name: _____		Prescriber Name: _____	
Address: _____		State License: _____ NPI #: _____	
City, State, Zip: _____		DEA: _____ Phone: _____	
Phone: _____ 2 <sup>nd</sup> Phone: _____		Address: _____ Fax: _____	
DOB: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		City, State, Zip: _____	
Weight: _____ Ht: _____ Date: _____		Contact Person: _____	
E-mail address: _____		Phone: _____	

INSURANCE INFORMATION: Copy and attach the front and back of insurance and prescription card(s)			
Primary Insurance: _____		RX Card (PBM): _____	
City, State, Zip: _____		BIN: _____ PCN: _____	
Member ID #: _____ Phone: _____		City, State, Zip: _____	
Plan #: _____ Group #: _____		Plan #: _____ Group #: _____	

DIAGNOSIS / CLINICAL INFORMATION	
Primary ICD-10 code: _____	Diagnosis <input type="checkbox"/> G36.0 Neuromyelitis optica <input type="checkbox"/> Other: _____
Is the patient anti-aquaporin-4 antibody positive? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Test pending	
Prior NSMOD therapies tried/failed: _____	
Hep B vaccination: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: _____	Does the patient have active Hepatitis B infection? <input type="checkbox"/> Yes <input type="checkbox"/> No
Hepatitis B screening: <input type="checkbox"/> Hepatitis B surface antigen <b>HBsAg</b> results: <input type="checkbox"/> Positive <input type="checkbox"/> Negative Date: _____	
<input type="checkbox"/> HB core antibody <b>HBcAb+</b> results: <input type="checkbox"/> Positive <input type="checkbox"/> Negative Date: _____	
Does the patient have active or latent TB infection? <input type="checkbox"/> Yes <input type="checkbox"/> No	Tuberculosis screening: <input type="checkbox"/> Positive <input type="checkbox"/> Negative Date: _____
First two loading doses completed: <input type="checkbox"/> Yes <input type="checkbox"/> No <b>Note:</b> Uplizna loading doses must be administered in a controlled setting.	
Expected date of first/next infusion: _____	
<input type="checkbox"/> NKDA <input type="checkbox"/> Known drug allergies: _____	
Concurrent Meds: _____	

PRESCRIPTION / ADMINISTRATION			
Medication	Dose	Directions	Quantity / Refills
<input type="checkbox"/> Uplizna® (inebilizumab injection) Initial dose (two infusions) Note: Loading doses must be administered in a controlled infusion site.	100mg/10mL SDV Each dose 300mg/30mL diluted in 250mL of 0.9% sodium chloride injection for final concentration of 1.1mg/mL	Infusion 1: 300mg in 250mL of 0.9% NS. Infusion 2: (2 weeks later): 300mg in 250mL of 0.9% NS. Start infusion at 42mL per hour for the first 30 minutes, increase to 125mL per hour for the next 30 minutes, then increase to 333mL per hour until finished. Duration: 2 hours or longer Monitor patient for at least one hour after infusion completion for infusion reaction.	<input type="checkbox"/> 6 vials - No refills
<input type="checkbox"/> Uplizna® (inebilizumab injection) Maintenance dose (one infusion)	100mg/10mL SDV Each dose 300mg/30mL diluted in 250mL of 0.9% sodium chloride injection for final concentration of 1.1mg/mL	Every 6 months (from first infusion) infuse 300mg in 250mL of 0.9% NS. Start infusion at 42mL per hour for the first 30 minutes, increase to 125mL per hour for the next 30 minutes, then increase to 333mL per hour until finished. Duration: 2 hours or longer Monitor patient for at least one hour after infusion completion for infusion reaction.	<input type="checkbox"/> 3 vials Refills: <input type="checkbox"/> 0 <input type="checkbox"/> 1

All Uplizna® orders to be administered via pump and peripheral line unless otherwise instructed.

Additional Medication and Supplies for Home Infusion	
<b>Premedication Orders</b> Acetaminophen 650mg PO 30 min prior to infusion; Diphenhydramine 50mg PO 30 min prior to infusion; Methylprednisolone 100mg IV 30 min prior to infusion. <input type="checkbox"/> Other: _____	Send quantity sufficient for medication infusion,  All caregivers and ancillaries to be given per protocol from product package insert.
<b>Fluids for Reconstitution and Administration</b> 0.9% NaCl 250mL x2 (initial dose); 0.9% NaCl 250mL (maintenance dose) 0.9% NaCl Flush 10mL (3 mL pre- and post-infusion to maintain peripheral line patency)	If patient requires specific directions on additional medications or supplies, please provide change on the next page and sign.

0.9% NACL 50mL 0.9% NACL 100mL	
-----------------------------------	--

**Hypersensitivity / Anaphylaxis Orders\***  
In the event of anaphylactic reaction, stop infusion of drug immediately. Start NS 15mL/hour; 0.9% NS 100mL.  
Medicate with epinephrine pen auto-injector 0.3mg/0.3mL IM as needed for anaphylaxis. Call **911**, physician, or paramedic.

I authorize ancillary supplies or medical equipment necessary such as needles, syringes, etc. to administer the therapy as needed for administration.

Skilled nursing visit as needed to establish venous access, administer medication, and assess general status and response to therapy.  
\*If nursing services will be required for therapy administration, the home health nurse will call for additional orders per state regulations.

**SIGNATURE**

X \_\_\_\_\_ Date: \_\_\_\_\_  
(Product Substitution Permitted)

**CONFIDENTIALITY STATEMENT:** This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited.

If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

Fax completed form to: (800) 783-9146 - Thank you for using BioTek reMEDys®